单倍体移植与同胞全合及无关供者移植治疗成人标危急性淋巴细胞白血病首次完全缓解的比较
该回顾性研究纳入348例成人标危急性淋巴细胞白血病首次完全缓解患者,比较单倍体(127例)、同胞全合(144例)和无关供者(77例)移植结局;单倍体移植的II-IV级急性移植物抗宿主病累积发生率高于同胞全合,但III-IV级、移植相关死亡率、复发率、总生存、无病生存及无GVHD无复发生存均无显著差异;单倍体移植可作为缺乏全合供者患者的有效替代选择。
要点
- 单倍体移植的II-IV级急性GVHD累积发生率39.5%,高于同胞全合移植的24.0%(P=0.020),但与无关供者移植的40.3%相近。
- 单倍体、同胞全合和无关供者移植的5年总生存率分别为70.1%、73.7%和69.8%,无显著差异(P=0.525)。
- 单倍体移植的5年无病生存率为68.7%,与同胞全合移植的67.3%和无关供者移植的63.7%无显著差异(P=0.606)。
核心结论
- 单倍体移植结局与同胞全合及无关供者移植相当,可作为缺乏全合供者的标危成人急性淋巴细胞白血病首次完全缓解患者的有效替代选择。
研究设计与样本
- 回顾性研究纳入348例成人标危急性淋巴细胞白血病首次完全缓解患者,其中单倍体移植127例、同胞全合移植144例、无关供者移植77例。
主要发现
- II-IV级急性GVHD累积发生率单倍体组39.5%、同胞全合组24.0%、无关供者组40.3%(P=0.020)。
- III-IV级急性GVHD发生率单倍体组11.4%、同胞全合组7.7%、无关供者组13.5%(P=0.468)。
- 5年移植相关死亡率单倍体组16.4%、同胞全合组11.6%、无关供者组19.6%(P=0.162);5年复发率分别为14.8%、21.1%、16.7%(P=0.231)。
- 5年总生存率单倍体组70.1%、同胞全合组73.7%、无关供者组69.8%(P=0.525);5年无病生存率分别为68.7%、67.3%、63.7%(P=0.606)。
- 3年无GVHD无复发生存率单倍体组50.8%、同胞全合组54.9%、无关供者组52.2%(P=0.847)。
临床怎么用
- 作者认为,对于缺乏全合供者的标危成人急性淋巴细胞白血病首次完全缓解患者,单倍体移植是有效的替代选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We retrospectively investigated outcomes of haploidentical donor (HID) transplant for adults with standard-risk acute lymphoblastic leukaemia (ALL) in first complete remission (CR1) compared with human leucocyte antigen (HLA)-matched sibling donor (MSD) and HLA-matched unrelated donor (MUD) transplants. A total of 348 adult patients were enrolled, including 127 HID, 144 MSD and 77 MUD recipients. The cumulative incidence of grade II-IV acute graft-versus-host disease (aGVHD) was 39·5%, 24·0% and 40·3% for HID, MSD and MUD, respectively (P = 0·020). However, there was no difference in grade III-IV aGVHD (11·4%, 7·7%, 13·5%, respectively, P = 0·468). The 5-year cumulative transplant-related mortality was 16·4%, 11·6% and 19·6% (P = 0·162), the 5-year relapse rate post-transplantation was 14·8%, 21·1% and 16·7% (P = 0·231), the 5-year overall survival was 70·1%, 73·7% and 69·8% (P = 0·525), and the 5-year disease-free survival was 68·7%, 67·3% and 63·7%, respectively (P = 0·606). Furthermore, the 3-year GVHD-free, relapse-free survival was not different (50·8%, 54·9% and 52·2%, respectively, P = 0·847). Our results indicate that the outcomes of HID transplants are equivalent to those of MSD and MUD, and that HID transplantation is a valid alternative for standard-risk adults with ALL in CR1 who lack matched donors.
引用
- Han LJ, Wang Y, Fan ZP, et al. Haploidentical transplantation compared with matched sibling and unrelated donor transplantation for adults with standard-risk acute lymphoblastic leukaemia in first complete remission. Br J Haematol. 2017. PMID: 28737249. doi:10.1111/bjh.14854
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。